- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has been invited to present at Friedland Investment Events' Life Sciences Conference in New York. The Conference will be held November 1st at the DoubleTree Hotel Time Square, 1568 Broadway (47th and 7th), New York.
The Life Sciences Conference will feature presentations by senior management of publicly traded companies in the biotech, healthcare, medical devices and pharmaceutical industries.
Dr. Amit Kumar, President and CEO of CombiMatrix Corporation will review current operations and the company's plans for the future. Interested investors and shareholders may attend this presentation scheduled for 11:30 a.m. Eastern on November 1, 2007. Attendance is free for qualified and approved members of the financial community and investors, but tickets are required. Participation is limited to ensure quality opportunities to network, so register early for this premier event by contacting Ross Dimaggio at Friedland Events at 609-360-0584.
ABOUT FRIEDLAND INVESTMENT EVENTS
Friedland Investment Events LLC, the sponsor of the Global Equities Conference, is the world's largest sponsor of financial and investment events, sponsoring hundreds of conferences, luncheons, dinners, cocktail receptions and road shows annually throughout the United States.
About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology company that develops and sells proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security, as well as other potential markets where our products and services could be utilized. The technologies we have developed include methods to produce DNA arrays for use in identifying and determining the roles of genes, gene mutations and proteins. These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form S-1, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Fax: (425) 493-2010
Copyright © PrimeNewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Spain nanotechnology featured at NANO KOREA 2015 June 26th, 2015